Avivomed, a Minneapolis MI-based development stage, medical device company, raised $32M in Series A funding.
The backers were not disclosed.
The company intends to use the funds to pursue the development and commercialization of innovative neuromodulation technology platforms to treat large patient populations suffering from chronic diseases.
Avivomed is led by newly appointed President and CEO Steve Masson, an experienced senior executive with 40 years in the medical device business, including over 30 years in active implantable devices. He has previously held management roles for over 25 years, and has served in general management, research and development, and operational positions in both venture capital-backed startups and larger, revenue-driven companies, such as Cordis, Ventritex, InnerPulse, and NeuroTronik.
The company is also based in Ireland.
FinSMEs
06/12/2021